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Abstract 
The seeds of Ginkgo biloba are commonly eaten in Japan, Korea and China, but it is important to know 
that they can be responsible for poisoning, especially in young children. Poisoning due to Ginkgo 
biloba seeds must also be considered as a possible clinical event in European countries, where Asian 
cuisine has recently become popular. This paper reports the case of a 23-months-old previously healthy 
male child who experienced two afebrile tonic-clonic seizures after the consumption of an unknown 
amount of Ginkgo seeds. The poisoning was identified by searching both in blood and urine for  4’-O-
methylpyridoxine (MPN) as a specific biomarker for ginkgo poisoning, using an optimized and 
validated HPLC method with fluorimetric detection. The MPN concentrations in serum were 16.5 and 
6.2 ng/mL 14 and 20 hours after the exposure, respectively, while the urine concentration was below 
the limit of detection (1.35 ng/mL). The involvement of ginkgo seeds in the described poisoning was 
confirmed by searching ginkgolide terpene lactones in urine, where the ratio between excreted 
ginkgolide A:B:C was 1:40:2. The analytical data obtained by looking for biomarkers in serum and 
urine demonstrate that even low values of MPN/ginkgolide concentration can be responsible for 
convulsions and other adverse effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Ginkgo biloba (commonly known as ginkgo or Maindenhair tree) is an ancient tree with distinctive 
fan-shaped leaves, belonging to the family of Ginkgoaceae. Leaves and seeds are the parts most 
usually consumed, both as food (roasted or cooked seeds) and as extracts in food supplements and 
traditional medicines. The leaf extract is widely used in Europe as a traditional drug to improve the 
symptoms of early-stage Alzheimer's disease, vascular dementia, peripheral claudication and tinnitus of 
vascular origin.1-4 The adverse effects of Ginkgo biloba preparations containing leaves are numerous; 
approximately 30% of these cases are due to interaction with therapeutic drugs, including acetyl 
salicylic acid, ibuprofen and warfarin.5 
The haemorrhagic complications, due to poisoning or interaction with prescription drugs, are probably 
due to the antiplatelet activity of ginkgosides, and in particular of Ginkgolide B6. 
Ginkgo biloba seeds are commonly eaten in Japan, Korea and China for their nutritive value, but it is 
important to know that they can be responsible for poisoning, especially in young children.7,8 Even 
though they are infrequent, clinical cases of ginkgo seed poisoning show severe symptoms, including 
tonic or clonic convulsion, vomiting, irritability and loss of consciousness.7-9  
Poisoning by ginkgo seeds is due to the neurotoxic compound 4'O-methylpyridoxine (MPN), which is 
chemically related to vitamin B6 and interfere with its biosynthesis, metabolism and function. The 
chemical structures of MPN and piridoxine are reported in Fig. 1.  
Ginkgo biloba seeds contain MPN at concentrations ranging between 170 and 400 mg/g of raw seeds. 
10-13 The toxin is relatively heat-resistant so that cooking or other treatments only partially inactivate 
it.14-16 
Kajiyama & Fujii (2002)7 described a case of poisoning in a 2-year-old girl who showed unexplained 
convulsions with vomiting, diarrhoea and irritability. The event was associated with the ingestion of 50 
to 60 roasted ginkgo seeds, as reported by the parents. Similarly, a case of poisoning was described in 
another 2-year-old girl who had eaten about 50 ginkgo seeds 4 hours before the onset of symptoms 7 
and a case of poisoning with ginkgo nuts was observed in a healthy 36-year-old woman, who 
consumed 70-80 seeds cooked in a microwave oven.9 The pathophysiologic mechanisms responsible 
for convulsions related to ginkgo poisoning are not fully understood. As known from in vivo studies, 
4’-O-methylpyridoxine (MPN) competes with vitamin B6, which is a cofactor of glutamate 
decarboxylase; as a consequence, MPN indirectly inhibits the activity of this enzyme resulting in a 
decrease of the -aminobutyric acid (GABA) level in brain, which predisposes to convulsions.9,17,18 
 
The study reported in this paper describes a case of ginkgo poisoning which occurred in Switzerland in 
a 2-year-old boy, where the association with the ingestion of ginkgo seeds was confirmed by measuring 
biomarkers both in blood and urine.  
 
 
Materials  
Clinical data 
A 23-months-old previously healthy male child of Asian origin experienced two afebrile tonic-clonic 
seizures for 15-30 seconds. He had had a 2-hour period of vomiting and somnolence. The parents 
reported that the child ingested an unknown amount of Ginkgo seeds 10 hours before the beginning of 
symptoms. The subsequent clinical course was uneventful with full recover. Blood samples were taken 
14 and 20 hours after the ingestion of seeds, while urine was collected only 14 hours after intake.  The 
patient’s family consented to the publication of this case report. 
 
 
Purified standards  
4’-O-methylpyridoxine (MPN)  
The toxin 4'-O-methylpyridoxine was not commercially available at the time of the study, so that we 
synthesized it ourselves according to the method described by Harris (1940).19 A mixture of 2-methyl-
3-hydroxy-4,5-dihydroxymethylpyridine hydrochloride (10.25 g, 50.0 mmol) and sodium methoxide 
(2.71 g, 50.0 mmol) in methanol (80 mL) was heated in a bomb tube at 130 °C for 12 h. The solvent 
was evaporated off and the residue treated with acetone and filtered to remove the sodium chloride. 
The organic solution was concentrated to give an oily residue, which was chromatographed on silica 
gel. Elution with ethyl acetate/methanol (80:20, v/v) yielded 5.2 g (56.5%) of 2-methyl-3-hydroxy-4-
methoxymethyl-5-hydroxymethylpyridine as an orange oil. The compound was dissolved in ethanol 
(20 mL) and 2.6 M ethanolic HCl (15 mL) was added while stirring. The suspension was heated at 
reflux and, after cooling to 0°C, filtered to give 4.1 g (37.5%) of the compound as a white solid; the 
final product was chemically characterized to confirm the identity, as described in Results and 
Discussion. 
  
Ginkgolides 
Reference standards for (-)-bilobalide and ginkgolides A, B, C were kindly supplied by PhytoLab 
(Vestenbergsgreuth, Germany).  
Reagents 
The reagents used in the study were: acetone for HPLC (Farmitalia Carlo Erba, Milano, Italia); 
acetonitrile, methanol, water for HPLC and 37% hydrochloric acid (VWR International, Fontenay-
sous-Bois, France); absolute ethanol for analysis (Merck KGaA, Darmstadt, Germany); ethyl acetate 
for HPLC  99.9%, L-ascorbic acid, formic acid  98%,  and heptafluorobutyric acid  99% (Sigma-
Aldrich, Steinheim, Germany); ethylenediaminetetraacetic acid (EDTA, Bio-Rad Laboratories, 
Hercules, California, USA). 
 
 
Methods 
 
Quantification of 4’-O-methylpyridoxine (MPN) in serum  
Preparation of standard solutions and serum sample  
Aliquots of 1 mg of MPN were solubilised in 10 mL of 0.1 M HCl, the final concentration being 100 
μg/mL. Further standards of 1 and 0.1 μg/mL (prepared by dilution in 0.1 M HCl) were added to a 
healthy volunteer's serum present in our seroteque ("blank" sample) to obtain the final concentrations 
of 4.5, 7.2, 13.5, and 27 ng/mL of MPN, which were used to prepare the test for linear regression. 
Aliquots of 500 L of these solutions or of the blank/patient's serum were added to 500 L of acetone; 
the resulting solutions were thoroughly vortexed, and centrifuged at 2500 rpm for 5 minutes (Hermle 
Labortechnik GmbH, Wehingen, Germany). The supernatants were filtered through a 0.45 m syringe 
filter (VWR International, Fontenay-sous-Bois, France) and injected into the HPLC. 
 
Chromatographic conditions 
A HPLC method combined with fluorimetric detection was used for the rapid separation and 
quantification of 4’-O-methylpyridoxine (MPN) in the patient's serum and urine. The equipment 
consisted of an Intelligent PU-880 pump (Jasco, Tokyo, Japan), a fluorescence Detector FP-1520 
(Jasco, Tokyo, Japan), a sample injection valve Rheodyne 7725 with 20 L loop (Cotati, California, 
USA), a column of Inertsil ODS-2, 125 x 4.6 mm, particle size 5 m (GL Sciences Inc., Tokyo, Japan). 
ChromNAV software (Jasco, Tokyo, Japan) was used for integration. The analysis was performed by 
isocratic elution at a flow rate of 1 mL/min with the mobile phase: 0.1% heptafluorobutyric acid in 
water, and acetonitrile, 90:10 (v/v). The column was heated at 40°C, and the fluorescence detector was 
set at 290/400 nm (ex/em). 
Method validation 
The HPLC method has been validated as described in Results. The suitability of the chromatographic 
system was daily checked by using the ChromNAV software (Jasco, Tokyo, Japan). 
 
Detection of ginkgosides and bilobalide in urine  
Preparation of standard solutions  
Aliquots of 1 mg of each standard (ginkgolides A,B, C and bilobalide) were dissolved in 10 mL of 
water to a final concentration of 100 μg/mL. Dilutions were carried out in order to obtain a final 
mixture containing 10 µg/mL of each standard. 
 
Sample preparation 
The urine sample was prepared according to Dew et al., (2014).20 It was thawed at room temperature 
immediately before extraction, placed in an ultrasonic water bath (5 min), then vortexed (30 sec) to 
ensure homogeneity. The sample was extracted in triplicate. Each 200 µL aliquot of urine was 
combined with 20 µL of an aqueous mixture of ascorbic acid (1% w/v) and EDTA  (0.1% w/v), 100 µL 
of ethanol and 1 mL of ethyl acetate in a 1.5 mL centrifuge tube. The solution was vortexed (30 sec), 
placed in an ultrasonic water bath (5 min) and vortexed again to extract soluble compounds. The tubes 
were centrifuged (Hermle Labortechnik GmbH, Wehingen, Germany) at 17000 rpm for 10 min at 8°C 
and the upper layer was removed. A second 1-mL aliquot of ethyl acetate was added to the pellet, and 
the extraction procedure repeated. All extracts were dried under nitrogen at room temperature and 
frozen at – 20°C. On the day of analysis, the second extracts were solubilized in 70 µL of ethanol, 
vortexed (30 sec), placed in an ultrasonic water bath (5 min) and vortexed again. A 50-µL aliquot of 
this solution was combined with the corresponding first dried extract, which was similarly vortexed 
and sonicated. A 50 µL aliquot of ascorbic acid solution (0.2%, w/v) was added to the combined 
extract, which was then vortexed and centrifuged at 17000 rpm at 8°C for 10 min. The supernatant was 
placed in a HPLC vial, which was capped and kept at 8°C until the analysis. 
 
Chromatographic conditions 
A HPLC-MS method was applied for the rapid separation of ginkgolides and bilobalide in urine. The 
equipment included a HPLC Surveyor MS Pump Plus coupled to an ion trap mass spectrometer LCQ 
Deca XP MAX (Thermo Electron Co, San Jose, CA, USA), a column Kinetex 2.6  µm PFP, 100 A, 
100 x 2.1 mm (Phenomenex, Torrance, California, USA), and a Surveyor Autosampler Plus (Thermo 
Electron Co, San Jose, CA, USA). The software Excalibur® Release 2.0 SR2 (Thermo Electron, San 
Jose, CA, USA) was used for integration. The analysis was performed according to Dew et al (2014)18, 
using a gradient elution at a flow rate of 0.3 mL/min; the mobile phases were: A) 
water:methanol:formic acid, 94.9:5:0.1 (v/v/v), and B) methanol:water:formic acid 95:4.9:0.1 (v/v/v). 
The gradient elution was set up as shown in Table 1. The autosampler and column oven temperatures 
were set at 8°C and 35°C, respectively, and the injection volume was 20 µL. MS analysis was 
performed in negative ionization mode. The capillary temperature was 300°C, the nebulized gas was 
nitrogen, sheath gas flow was 50 arb and sweep gas flow was 10 arb. 
 
Results and discussion 
Consumption of Ginkgo biloba seeds is quite common in Asian cuisine and in Oriental countries with a 
normally rather low risk. Traditionally, the seeds are roasted or boiled to reduce the activity of the 
neurotoxin, 4'-O-methylpyridoxine. Because of the rapid diffusion of oriental cuisine in other countries, 
the risk could be greater there from the unsuitable intake of ginkgo seeds. Both authorities and the 
population should be carefully informed of this possibility. To our knowledge, the case of gingko seed 
poisoning described in this paper is the first to occur in Europe.  
The objectives of this work were: 1) to confirm the suspected intoxication by Ginkgo biloba seeds; 2) 
to develop  accurate methods of measuring biomarkers useful in identifying similar events in the future. 
In fact, because of the severity of symptoms and the prevalent involvement of children, a clear 
methodological approach is necessary to allow rapid diagnosis and treatment.  
In this case, a 23-months-old male child was brought to the emergency department after tonic-clonic 
seizures in both arms, and after discussion with the parents we hypothesized  that the cause was 
intoxication by Ginkgo biloba seeds, so that serum and urine were collected and immediately sent for 
biomarker analysis. 
On the basis of the paper by Hori et al (2004),10 a HPLC method for detection of the neurotoxin MPN 
was set up, with some modifications as described in Methods. Because purified MPN was not available, 
we synthesized it, as described in Materials and Methods. The final product was checked for quality 
and purity. Purity of 4'O-methyl pyridoxine was 90%, the remaining 10% being the pyridoxine used as 
a starting reagent in the synthetic procedure. Since pyridoxine did not interfere with the analysis, this 
standard was used as a reference compound for quantification, and a correction factor for purity was 
applied. 
The identity of synthesized MPN was confirmed by its melting point of 179-180 °C, and NMR analysis 
1H NMR (DMSO-d6)  10.90 (bs, 1 H) 8.13 (s, 1 H), 5.75 (bs, 2 H), 4.68 (s, 2 H), 4.65 (s, 2 H), 3.29 (s, 
3 H), 2.63 (s, 3 H). Anal. Calcd for C9H14ClNO3.  
A problem arose during the setting up of the method was the different performance shown by MPN 
standard in water/buffer solutions, compared to human serum or urine. For this reason the linear 
regressions were prepared in human serum/urine.  
 
Validation of the method used for the quantification of 4’-O-methylpyridoxine (MPN) in serum  
The method for the quantification of MPN in serum was validated according to the guidelines 
described by Peters et al. (2007),21 for the following parameters: selectivity, linearity, accuracy, 
precision and sensitivity (LOD and LOQ). Furthermore, the System Suitability Test (SST) was 
performed according to the current FDA Guidelines on Bioanalytical Method Validation.22  
 
System suitability test (SST) 
The following parameters were calculated using the ChromNAV software: retention factor (K), 
separation factor between two neighbouring peaks (), peak tailing factor and column efficiency 
(number of theoretical plates). The analysis was performed in triplicate. 
Table 2 shows the results of the SST obtained from the analysis of the "blank" serum spiked with MPN 
at the final concentration of 30 ng/mL.  
The parameters show that the chromatographic system used in this assay was highly efficient and 
suitable for the quantification of MPN, having retention factor (K) ≥ 2, separation factor ()  > 1, 
symmetry factor (SF)  < 2.20 
Selectivity 
The possible interaction between analytes and endogenous matrix components was investigated by 
adding standard MPN to the "blank" serum (final 30 ng/mL). Peak areas of compounds coeluting with 
the analytes should be less than 20% of the peak area of sample at LOQ. As shown in Fig. 2, MPN can 
be clearly identified; no peak at the retention times of MPN had an area exceeding 20% at LOQ values.  
 
Linearity 
Standard solutions (1 and 0.1 g/mL) were added to a "blank" serum to have final concentration of 5, 8, 
15 and 30 ng/mL; these solutions were prepared as described in “sample preparation” (3.2.2) and 
analysed with three independent injections. 
Linear regression was obtained by plotting the areas of analyte peaks vs the nominal concentrations. 
The calibration curve equation and the corresponding correlation coefficient (R2) were calculated 
taking into account the purity of the standard (90%). The linear regression, used to calculate MPN 
concentrations in serum is illustrated in Fig. 3. The method was linear between 4.5 and 27 ng/mL, as 
shown by the correlation coefficient (R2) higher than 0.99. The linear regression equation was 
y=13872X+23918, where y refers to the peak area and x refers to concentration. 
 
Accuracy and precision 
Accuracy and precision were determined spiking "blank" serum samples with two concentrations of the 
MPN standard (0.1 and 1 µg/mL) in order to have final concentrations at 6 and 25 ng/mL 
(corresponding to actual concentrations of MPN of 5.4 and 22.5 ng/mL, respectively). 
Accuracy was calculated as the percent of variation between the experimentally measured means and 
the nominal values. Precision was determined by calculating the variation coefficient (RSD%) of the 
peak areas of five replicates injected in the same day. 
Table 3 shows the results obtained for accuracy and precision. Being RSD% <15%, the method must 
be considered precise, and since the calculated accuracy was always within ±15% of the nominal 
concentration, the method can be considered accurate. 
 
Sensitivity (LOD and LOQ) 
The sensitivity of the analytical method was evaluated by determining the limit of detection (LOD) and 
the limit of quantification (LOQ). LOD and LOQ were determined spiking "blank" serum samples with 
decreasing concentrations of MPN standard: LOD was established at a signal-to-noise ratio of 3 and 
LOQ at a signal-to-noise ratio of 10. The LOQ was based on data obtained from 5 independent 
injections. 
LOD and LOQ for MPN measured in the "blank" serum were 1.35 and 4.5 ng/mL, respectively. The 
precision at LOQ was 13.9%, below the acceptable limit of 15%. All values reported above were  
suitable for an accurate determination of MPN in serum samples. 
 
Quantification of 4’-O-methylpyridoxine (MPN) in serum and urine 
Fig. 4 illustrates the results of MPN quantification in the patient's serum at 14 and 20 hours after eating 
Ginkgo biloba seeds (Panels B and C, respectively). Panel A of the same figure shows the 
chromatogram of MPN standard solution at the concentration of 0.1 g/mL. The presence of 
pyridoxine, as a residue of starting reagent, is clearly evident and was quantified in 10%. As discussed 
above, the elution time of this "impurity" does not interfere with the MPN determination in serum. 
MPN concentrations in the child's serum were 16.53±1.55 and 6.18±0.69 ng/mL (m±SD), at 14 and 20 
hrs from intake, respectively. MPN was also searched for in urine (data not shown) but values were 
below the limit of detection of 1.35 ng/mL. 
 
Identification of ginkgolide terpene lactones in urine  
Since MPN was undetectable in urine, a further confirmation of exposure to Ginkgo biloba seeds was 
done by searching ginkgolides and bilobalide in the child's urine. The use of terpenic lactones as 
urinary biomarkers of ginkgo intake has been considered previously and very recently, interesting 
results have been published by Dew and coworkers.20 The chemical structures of these molecules are 
illustrated in Fig. 1. The detection of ginkgolides (A,B,C) and bilobalide was obtained by HPLC 
coupled to mass spectrometry. Fig. 5 shows the results obtained by Total Ion Chromatography (TIC) 
and the Single Ion Monitoring (SIM) for the identification of the Ginkgo biloba biomarkers. Panel A 
shows the chromatograms associated with a mixture of standards at the concentration of 10 g/mL for 
each analyte. The absence of any interfering signal in the "blank" urine is shown in panel B and finally, 
the presence of ginkgolides in the child's urine is confirmed in panel C (see arrows). The most 
abundant compound was Ginkgolide B, with a urine concentration of approximately 40 g/mL; 
Ginkgolide A and C were present in concentrations close to 1 and 2 g/mL, respectively. Bilobalide 
was not detectable. 
 
Conclusions 
The case described in this paper shows that the poisoning due to Ginkgo biloba seeds must be 
considered as a possible clinical event also in European countries, where Asian cuisine has received a 
relatively recent popularity. Any introduction of new dietetic habits requires suitable information to be 
provided, as in the case of Ginkgo biloba seeds, which are appreciated also by children for their good 
flavour. Unfortunately, particularly for the youngest children they could represent a risk, as shown by 
case reports published in the scientific literature.7,8 In the case described here, poisoning was confirmed 
by identifying biomarkers both in blood and urine. Traditionally, 4’-O-methylpyridoxine (MPN) has 
been considered as the specific biomarker for ginkgo seed poisoning, both in blood and urine. 
Considering the different papers reporting cases of ginkgo seed poisoning (Table 4), it quite evident the 
difficulty in correlating the number of seed ingested with MPN serum concentration; moreover, the 
kinetic of MPN in serum and urine after exposure is complex and shows a significant variability. 
The case reported here showed a MPN serum concentration of 16.5 and 6.2 ng/mL after 14 and 20 
hours from the exposure, respectively. These values are below the concentrations measured by other 
authors (usually above 100 ng/mL) but, in agreement with our data, Hasegawa et al (2006)8 showed 
that a concentration of 37 ng/mL at 4 hours after the consumption of 50 ginkgo nuts was enough to 
induce vomiting and afebrile convulsion in a 2-year-old boy. Moreover, Kajiyama & Fjii (2002)7 
showed a very quick decrease of MPN concentration in serum: from 360 ng/mL after 9 hours from the 
exposure to < 15 ng/mL one hour later, indicating that the timing of sample collection could be critical 
in detecting the biomarker. 
The variability observed in the MPN serum concentration could be justified (at least partially) by the 
significant difference in MPN content measured in ginkgo seeds (172.8-404.2 g/g dry weight), 
supporting also data reported by different authors where the number of seeds necessary to produce 
fatalities varied from 15 and 574.6 According to the case described here, low values of MPN 
concentration can also be responsible for convulsions and adverse effects and it is known that MPN 
toxicity can be modulated by several factors, such as the patient's nutritional state, where a particular 
role can be played by the pyridoxine storage.7 
In contrast to some previous papers, MPN was not detectable in the child's urine, but the ginkgo 
poisoning was confirmed by the identification of ginkgolide terpenic lactones, which are considered 
biomarkers for the acute consumption of Ginkgo biloba derivatives.18 
The correct diagnose of ginkgo poisoning, which usually require vitanin B6 administration7,8,10,23, is 
important for suitable treatment of  the patient and to avoid fatalities, so that the identification of MPN 
in serum or urine could be very useful. A sensitive method for the detection of this biomarker was 
optimized and validated specifically for the cases of poisoning by ginkgo seeds. We showed in this 
study that poisoning can be severe also when the level of MPN in urine is not detectable; in these cases, 
the identification and semi-quantitation of gikgolide terpene lactones in urine provides a valuable tool 
in confirming the acute consumption of ginkgo seeds. Moreover, we observed that the ratio between 
the three main ginkgolides (A:B:C) was approximately 1:40:2. The relative abundance of excreted 
ginkgolides was different from that observed by Dew et al (2014) 20, where ginkgolide A was the most 
abundant terpenoid in urine after the consumption of leaf extract (109% of quantity administered). If 
confirmed by other studies, this specific ginkgolide relative abundance in urine, associated with the 
absence/very low quantity of bilobalide, could be also used to distinguish between poisoning due to 
ginkgo leaves and that from seeds. Finally, the case described indicates that population, family doctors, 
and authorities need to be informed on the specific risk deriving from food containing ginkgo, taking 
also into consideration the increasing diffusion worldwide of oriental cuisine. 
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